New England’s tech and life sciences firms inked lots of deals in the last week, with the software sector being particularly active. —Advanced RenewableEnergy Company of Nashua, NH, raised $5 million of a $10 million equity round, according to regulatory filings. Nicknamed ARC Energy, the company makes equipment for growing and processing the sapphire crystals … Continue reading “MPM Collects $140M for Fifth Fund, NEXX Files for IPO, Nuance Advances on Mac Market, & More Boston-Area Deals News”
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
Presidents Day
Posting will be light today as Xconomy is closed for Presidents Day. We’ll be back tomorrow full force. Meanwhile, enjoy the holiday!
Zafgen Plans Weight-Loss Study, Infinity CEO Perkins Plans for Growth, Boston Scientific Cuts 1000+ Jobs, & More Boston-Area Life Sciences News
This week we’ve got another crop of great interviews with the founders and executives of some of New England’s most fascinating life sciences companies. —Zafgen CEO Tom Hughes filled Luke in on his Cambridge, MA-based startup’s plans to begin human tests of its anti-obesity drug, which the company hopes will be the first drug to … Continue reading “Zafgen Plans Weight-Loss Study, Infinity CEO Perkins Plans for Growth, Boston Scientific Cuts 1000+ Jobs, & More Boston-Area Life Sciences News”
ATG Banks $101M, Veracode Collects $12M, & More Boston-Area Deals News
It’s only been a few days since I last rounded up the deals news from New England’s tech and life sciences companies, but there are still a few new transactions to report. —Irvine, CA-based Allergan (NYSE:[[ticker:AGN]]) revealed in an earnings report that it acquired Medford, MA-based biomaterials maker Serica Technologies late last year. Financial terms … Continue reading “ATG Banks $101M, Veracode Collects $12M, & More Boston-Area Deals News”
Ironwood Goes Public, Glasshouse and BG Medicine Aim to Do the Same, Vivox Collects $6.8M, & More Boston-Area Deals News
For the first time in as long as I can remember, IPOs dominated the New England tech and life sciences deals news this week. —Glasshouse Technologies, an IT consulting firm in Framingham, MA, indicated in an SEC filing that it’s planning an initial public offering worth as much as $75 million. Glasshouse, which is aiming … Continue reading “Ironwood Goes Public, Glasshouse and BG Medicine Aim to Do the Same, Vivox Collects $6.8M, & More Boston-Area Deals News”
Alnara Adds $35M, Harvest Power Teams Up with Waste Management, & More Boston-Area Deals News
We spent some time this week looking at the data on last year’s venture deals, big and small, while New England’s tech and life sciences companies announced some of the first deals of 2010. —All but one of the 10 biggest Boston-area private equity deals in 2009 were closed by life sciences firms, a survey … Continue reading “Alnara Adds $35M, Harvest Power Teams Up with Waste Management, & More Boston-Area Deals News”
Introducing Erin Kutz, Belatedly
You know a new hire is a good fit when by the end of her first day you’ve already forgotten that she’s new. And that’s just what happened when our new assistant editor, Erin Kutz, joined the Boston team a couple weeks ago. In fact, we so quickly forgot that she’s new that we forgot … Continue reading “Introducing Erin Kutz, Belatedly”
Vertex CEO on Building a Blockbuster, Genzyme Investor on Fixing Up the Firm, Cubist CEO on Pipeline and Patent Challenges, & More Boston-Area Life Sciences News
If in-depth interviews with some of the heaviest hitters in the New England life sciences industry are your cup of tea, this was the week for you. —Ryan had a fascinating chat with Jorge Conde, co-founder and CEO of Cambridge, MA-based Knome, about how the startup is evolving in the rapidly evolving field of personal … Continue reading “Vertex CEO on Building a Blockbuster, Genzyme Investor on Fixing Up the Firm, Cubist CEO on Pipeline and Patent Challenges, & More Boston-Area Life Sciences News”
Time Inc. Scoops Up StyleFeeder, Ironwood Sets Sights on Potential $266.7 M IPO, FloDesign Reveals $34.5M Financing, & More Boston-Area Deals News
It was a short week, but the list of deals that New England’s tech and life sciences firms inked in that span is a long one. Let’s dive in: —StyleFeeder, the Cambridge, MA-based personalized shopping website, was acquired by New York magazine publishing giant Time Inc. for an undisclosed sum. Lexington, MA-based Highland Capital Partners … Continue reading “Time Inc. Scoops Up StyleFeeder, Ironwood Sets Sights on Potential $266.7 M IPO, FloDesign Reveals $34.5M Financing, & More Boston-Area Deals News”
IkaSystems Raises $120M, New CEOs of Qteros, Bind, and Quanterix Dish the Dirt, & More Boston-Area Life Sciences News
This week Ryan and Luke had several great interviews with some of the newest CEOs in New England life sciences. Those and the rest of the week’s biotech, devices, and health IT news below. —Luke caught up with Steve Gullans, a managing director with Excel Venture Management, who reports that his Boston-based venture firm is … Continue reading “IkaSystems Raises $120M, New CEOs of Qteros, Bind, and Quanterix Dish the Dirt, & More Boston-Area Life Sciences News”
MLK Day
Posting will be light today as Xconomy’s offices are closed in observation of the Martin Luther King, Jr. Day of Service. For those of you looking for a way to pitch in in your own city or town, Serve.gov has a searchable database of volunteer opportunities. If you or your organization would like to aid … Continue reading “MLK Day”
A123Systems Invests in Fisker, Virtify Finds $15M, ATG Acquires InstantService, & More Boston-Area Deals News
Dealmaking was steady across the tech and life sciences industries in New England this week. —Enterprise software firm Progress Software (NASDAQ: [[ticker:PRGS]]) of Bedford, MA, acquired Santa Clara, CA-based Savvion for $49 million, net of Savvion’s cash. —Cambridge, MA-based life sciences software firm Virtify raised $15 million in a Series A financing, according to a … Continue reading “A123Systems Invests in Fisker, Virtify Finds $15M, ATG Acquires InstantService, & More Boston-Area Deals News”
Genzyme Reaches Agreement with Activist Investor, Charles River Closes Shrewsbury Lab, Lycera Comes to Cambridge, & More Boston-Area Life Sciences News
It was another crazy-busy week for New England’s life sciences firms, many of which closed small-to-medium sized venture financings. I’ll talk about those as part of Friday’s deals roundup, but in the meantime here are some of the other highlights: —Alnylam Pharmaceuticals CEO John Maraganore told Luke about his vision for the coming “RNA decade,” … Continue reading “Genzyme Reaches Agreement with Activist Investor, Charles River Closes Shrewsbury Lab, Lycera Comes to Cambridge, & More Boston-Area Life Sciences News”
Quattro Scooped Up By Apple, Medtronic Invests in GI Dynamics, EMC Acquires Archer, & More Boston-Area Deals News
New England’s tech and life sciences companies hit the ground running in the new year, inking a host of deals this week. —Data storage giant EMC of Hopkinton, MA, made a bold move into the market for governance, risk management, and compliance (GRC) with the acquisition of Overland Park, KS-based Archer Technologies. Archer will become … Continue reading “Quattro Scooped Up By Apple, Medtronic Invests in GI Dynamics, EMC Acquires Archer, & More Boston-Area Deals News”
Mullen to Relinquish Biogen Idec Reins, Joule to Test Ethanol Tech, Dicerna to Team with Kyowa Hakko Kirin, & More Boston-Area Life Sciences News
I’ve got a couple weeks’ worth of New England life sciences news to catch you up on, so let’s dive in. —Shares of Watertown, MA-based pSivida (NASDAQ: [[ticker:PSDV]]) jumped more than 50 percent after the company reported its treatment for diabetic macular edema, an eye disorder, did well in a clinical trial. The treatment employs … Continue reading “Mullen to Relinquish Biogen Idec Reins, Joule to Test Ethanol Tech, Dicerna to Team with Kyowa Hakko Kirin, & More Boston-Area Life Sciences News”
Enjoy the holidays, and watch this space…
The boys and I will be taking some much needed time off for the next week and a half, so posting will be light in the main blog and News Xpress sections. But keep your eyes peeled, because over in the Xconomist Forum things are going to be hopping right on through the New Year. … Continue reading “Enjoy the holidays, and watch this space…”
Biogen Drops Facet Bid, Aveo Reveals IPO Ambitions, Pfizer Partners with Adimab, & More Boston-Area Life Sciences News
New England’s drug developers and device makers are squeezing in a few more partnerships, acquisitions, financings, and strategic moves before the year’s end. —Acceleron Pharma, the Cambridge, MA-based biotech that’s building its own drug-making infrastructure rather that outsourcing the work, raised $10.9 million in equity financing, according to an SEC filing. $8 million comes from … Continue reading “Biogen Drops Facet Bid, Aveo Reveals IPO Ambitions, Pfizer Partners with Adimab, & More Boston-Area Life Sciences News”
Aveo Aims for $86M Debut, Exagrid Snags $16M, PatientKeeper Adds $13M, & More Boston-Area Deals News
In honor of the eighth day of Hanukah, here are the top eight deals of the last week. —Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:[[ticker:CBST]]) inked a deal to acquire San Diego-based Calixa Therapeutics for $92.5 million upfront, with as much as $310 million more in potential payments also on the table. The merger of the firms, … Continue reading “Aveo Aims for $86M Debut, Exagrid Snags $16M, PatientKeeper Adds $13M, & More Boston-Area Deals News”
Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News
Gadzooks, was this a busy news week for the biotech, devices, and healthcare IT sectors in New England. Here’s the lightning round version: —Luke examined Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]])’s efforts to create antibody drugs that can hit two targets at once. —Cambridge-based Parasol Therapeutics, an MIT spinoff developing treatments and diagnostics for influenza … Continue reading “Biogen Idec Board in Flux, Cubist Acquires Calixa, ImmunoGen Drug Passes Clinical Test, & More Boston-Area Life Sciences News”
5AM Gathers $200M Fund, Advanced Cell Technology Advances with $2.8 Million, Gloucester Picked up for $640M, & More Boston-Area Deals News
Lots of deals to report this week from New England tech and life sciences companies. —Gloucester Pharmaceuticals of Cambridge, MA, agreed to an acquisition by Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]). Gloucester will get $340 million in cash, plus $300 million in future milestone payments out of the deal, which is expected to close by the … Continue reading “5AM Gathers $200M Fund, Advanced Cell Technology Advances with $2.8 Million, Gloucester Picked up for $640M, & More Boston-Area Deals News”
Facet Rejects Biogen’s Latest Offer
The board of Redwood City, CA-based Facet Biotech (NASDAQ:[[ticker:FACT]]) unanimously recommended that shareholders reject the latest tender offer from Cambridge, MA-based Biogen Idec (NASDAQ:[[ticker:BIIB]]), saying that the $17.50 per-share offer, which would value Facet at about $438.7 million, was inadequate. Biogen called the bid, made a week ago, its “best-and-final offer.” Facet nonetheless says it … Continue reading “Facet Rejects Biogen’s Latest Offer”
A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News
New England’s life sciences firms and their investors seemed to be exchanging some early holiday gifts this week. —Vertex (NASDAQ: [[ticker:VRTX]]) completed the latest in a string of large financing and licensing deals. In this one, the Cambridge, MA-based developer of drugs for hepatitis C and cystic fibrosis sold a total of $500.5 million worth … Continue reading “A Graceful Exit for Gloucester, Pink Slips at Sermo, A Half a Billion Bucks for Vertex, & More Boston-Area Life Sciences News”
$443 million for Vertex, $25.5M for Forma, $8M for Contour Semiconductor, & More Boston-Area Deals News
The dollar amounts ranged from the modest (FitnessKeeper) to the mammoth (Vertex) for New England tech and life sciences deals this week. —Boston’s FitnessKeeper, maker of the RunKeeper iPhone application, raised $400,000 from Cambridge, MA-based LaunchCapital and a group of individual investors. Wade chatted with FitnessKeeper founder and CEO Jason Jacobs about his plans for … Continue reading “$443 million for Vertex, $25.5M for Forma, $8M for Contour Semiconductor, & More Boston-Area Deals News”
Forma Gets a $25.5M Fix, Novartis Bids Idera Adieu, Alnylam CEO Talks Strategy, & More Boston-Area Life Sciences News
Somewhere between the turkey prep and the post-pie catatonia, folks at New England’s life sciences companies managed to make some news. —Idera Pharmaceuticals (NASDAQ:[[ticker:IDRA]]), a developer of DNA- and RNA-based drugs, announced that Swiss drug giant Novartis will end its four-year-old collaboration with the Cambridge, MA-based firm in February. Idera still has active collaborations with … Continue reading “Forma Gets a $25.5M Fix, Novartis Bids Idera Adieu, Alnylam CEO Talks Strategy, & More Boston-Area Life Sciences News”
Xconomy is Growing; You Could Be Part of It
In the two and a half years that we’ve been live, Xconomy has been lucky to have some of the world’s best innovation journalists covering some of the nation’s most fascinating innovation hubs. But we’re well aware that there’s important tech and life sciences news happening beyond the borders of Boston, Seattle, and San Diego, … Continue reading “Xconomy is Growing; You Could Be Part of It”
Ironwood Nabs $75M in Deal With Japanese Firm, Gloucester Drug Gets FDA Approval, Alnylam Branches Into Biomanufacturing Tech, & More Boston-Area Life Sciences News
Several of New England’s life sciences firms had good news to report this week. —Ryan gave a run-down of the key insights to emerge from our Xconomy Forum on pharma innovation. Sirtris CEO Christoph Westphal, for example, offered insight into one of the biggest biological mysteries around the Xconomy office: how Luke manages to eat … Continue reading “Ironwood Nabs $75M in Deal With Japanese Firm, Gloucester Drug Gets FDA Approval, Alnylam Branches Into Biomanufacturing Tech, & More Boston-Area Life Sciences News”
Pulmatrix Pulls in $30.2M, GenArts Gobbles Up Wondertouch, BioVex Bags $30M, & More Boston-Area Deals News
Several of New England’s tech and life sciences firms got juicy deals the past week and a half. —Boston’s RunMyErrand, an online clearinghouse where busy people can find helpers for odd jobs, raised $1 million in a Series A venture financing round. The cash, from California investors Baseline Ventures and Maples Investments, will help the … Continue reading “Pulmatrix Pulls in $30.2M, GenArts Gobbles Up Wondertouch, BioVex Bags $30M, & More Boston-Area Deals News”
Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News
A number of New England’s life sciences companies had good news to report this week. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) reported results from clinical trials that indicate its experimental hepatitis C drug, telaprevir, could work well for patients who haven’t responded fully to standard treatments, and could be as effective taken twice a day … Continue reading “Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News”
Spark, Bezos Back Aviary, American Well Nabs $10M, Virdante Banks $30M, & More Boston-Area-Deals News
An unusually high percentage of this week’s New England tech and life sciences deals came from companies based in Boston proper. What’s up with that? —Spark Capital of Boston led a $7 million Series B investment in Long Island, NY-based Aviary. Backed also by Bezos Expeditions, Aviary makes cloud-based software for graphic design, audio editing, … Continue reading “Spark, Bezos Back Aviary, American Well Nabs $10M, Virdante Banks $30M, & More Boston-Area-Deals News”
European Regulators Question Antigenics and Biogen Idec Drugs, BioAssets Bags $30M in Option Deal, & More Boston-Area Life Sciences News
Europe’s drug regulators were not kind to a couple of Massachusetts biotech firms this week, but other New England life sciences companies had happier news to report. —European drug regulators turned down Lexington, MA-based Antigenics’ bid for approval to market vitespen (Oncophage), a “cancer vaccine” for patients with kidney cancer. Shares of Antigenics (NASDAQ: [[ticker:AGEN]]) … Continue reading “European Regulators Question Antigenics and Biogen Idec Drugs, BioAssets Bags $30M in Option Deal, & More Boston-Area Life Sciences News”
BioAssets Inks $30M Option Deal
Frazer, PA-based Cephalon (NASDAQ: [[ticker:CEPH]]) has agreed to pay $30 million for an option to acquire BioAssets Development Corporation, a Wellesley, MA-based company investigating spinal uses for existing and experimental drugs, according to a press release. Under the terms of the agreement, BioAssets will be eligible for an additional payment if Cephalon exercises the option, … Continue reading “BioAssets Inks $30M Option Deal”
HubSpot Spots $16M, Synageva BioPharma Secures $12M, Currensee Sews Up $6M, & More Boston-Area Deals News
Lots of venture news this week, with more than the usual number of software and Web companies making appearances. —Flexion Therapeutics raised $33 million in a Series A round led by Versant Ventures and joined by 5AM Ventures and Sofinnova Partners. The Woburn, MA-based startup believes it can cut the shepherd drugs from early development … Continue reading “HubSpot Spots $16M, Synageva BioPharma Secures $12M, Currensee Sews Up $6M, & More Boston-Area Deals News”
Flexion Pulls in $33M, Cubist Teams With Hydra, Charles River Makes Cuts, & More Boston-Area Life Sciences News
There was a steady serenade of news from New England’s life sciences companies this past week, with both the startups and the public firms chiming in. —Ryan profiled Boston BioCom, a Pfizer-backed startup aiming to commercialize life science discoveries from Russia. Based in, of course, Boston, the firm is also developing technology from the Massachusetts … Continue reading “Flexion Pulls in $33M, Cubist Teams With Hydra, Charles River Makes Cuts, & More Boston-Area Life Sciences News”
Cisco Snags Starent for $2.9B, Rocket Software Raises $91.9M, & More Boston-Area Deals News
Not much deals news to round up this week, thanks to the Monday holiday and the fact that last week’s roundup slipped to this week. But just in case you missed it… —Tewksbury, MA-based Starent Networks (NASDAQ:[[ticker:STAR]]) agreed to be acquired by technology giant Cisco (NASDAQ:[[ticker:CSCO]]) for a healthy $2.9 billion. Starent, which went public … Continue reading “Cisco Snags Starent for $2.9B, Rocket Software Raises $91.9M, & More Boston-Area Deals News”
Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News
It’s been a short week and a long weekend since last I rounded up New England’s life sciences news, but there were still a few stories worth mentioning. —Luke took an in-depth look at giant Amgen’s (NASDAQ: [[ticker:AMGN]]) efforts to boost its rate of success in getting new drugs to market. Though Amgen is based … Continue reading “Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News”
Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News
It was a busy week in the land of New England life sciences. Let’s dive in. —Luke did a massive analysis of the financial health of all the public biotech companies we follow the Boston area and the news… Well, it wasn’t good. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ:[[ticker:VRTX]]) brought in $155 million in cash by … Continue reading “Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News”
Google Backs Adimab, PVI Sweetens E Ink Deal, Sanofi-Aventis Partners With Merrimack Pharma, & More Boston-Area Deals News
As has been the case in recent weeks, M&A news featured prominently in this week’s New England tech and life sciences deals. —Harvard spinoff Tetraphase Pharmaceuticals of Watertown, MA, raised $10 million out of a planned $29.6 million equity financing round, the company indicated in an SEC filing. Tetraphase is developing new antibiotics to treat … Continue reading “Google Backs Adimab, PVI Sweetens E Ink Deal, Sanofi-Aventis Partners With Merrimack Pharma, & More Boston-Area Deals News”
Xconomy Channels Startups and Life Sciences
Notice anything new here? Over to the right a little… Little more… Next to the map? (Bear with me, loyal RSS and e-mail subscribers, this will all make sense in a minute.) Today marks the official launch of our new Startups and Life Sciences channels, whose homepages you can access via those handy new buttons … Continue reading “Xconomy Channels Startups and Life Sciences”
A123Systems Pulls Off Big IPO, PrimeraDx Grabs $20M, Conduit Labs Collects $3M, and More Boston-Area Deals News
The big news this week was obviously the A123Systems IPO, but quite a few other New England tech and life sciences firms had deals to report as well. —Mansfield, MA-based PrimeraDx—a developer of automated lab equipment spun off by Providence, RI-based Sention four years ago—raised $20 million in a Series C financing round. New investor … Continue reading “A123Systems Pulls Off Big IPO, PrimeraDx Grabs $20M, Conduit Labs Collects $3M, and More Boston-Area Deals News”
Biogen Idec Still Pursuing Facet Acquisition, Helicos Gets $10M Reprieve, Seaside Collects $30M for Autism Drug Development, & More Boston-Area Life Sciences News
New England’s diagnostics developers provided more than their fair share of life sciences news this week. —Rick Jones, CEO of Cambridge, MA-based Ascent Therapeutics, talked with Ryan about his startup’s progress developing new cancer drugs using so-called pepducin technology. Ascent’s lead candidate is emerging in recent tests as a potential rival to Genzyme’s plerixafor (Mozobil), … Continue reading “Biogen Idec Still Pursuing Facet Acquisition, Helicos Gets $10M Reprieve, Seaside Collects $30M for Autism Drug Development, & More Boston-Area Life Sciences News”
Biogen Tender Offer For Facet Begins
The Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) today began a $14.50-per-share tender offer for Redwood City, CA-based Facet Biotech (NASDAQ: [[ticker:FACT]]). Biogen initially proposed to acquire the California company, its partner in developing a new antibody drug for multiple sclerosis, on September 4, but Facet’s board rejected the deal, which is worth about $355 million … Continue reading “Biogen Tender Offer For Facet Begins”
A123 Plans $200M+ IPO, Seaside Sees $30M, Verivue Grabs $20.1M, & More Boston-Area Deals News
New England’s tech and life sciences companies have cut far too many deals to mention over the last week and a half, so we’re kicking it top-ten style for this installment of roundup. #10 GreenBytes of Ashaway, RI, completed an $8 million Series A financing from Waltham, MA-based Battery Ventures. The startup also unveiled a … Continue reading “A123 Plans $200M+ IPO, Seaside Sees $30M, Verivue Grabs $20.1M, & More Boston-Area Deals News”
Acceleron Aims for Anemia Cure, Mascoma to Pump Out Biofuels For Chevron, Genzyme Chief to Head Boston Fed, & More Boston-Area Life Sciences News
This week saw the demise of a couple of New England life sciences firms and the rise of several others. —Luke profiled the efforts of Cambridge, MA-based Acceleron Pharma to bring its lead drug candidate to market as a treatment for anemia. Previous experiments suggested the drug, ACE-011, would actually cause anemia, but in its … Continue reading “Acceleron Aims for Anemia Cure, Mascoma to Pump Out Biofuels For Chevron, Genzyme Chief to Head Boston Fed, & More Boston-Area Life Sciences News”
Highland Leads $9M InXpo Deal
Highland Capital Partners of Boston led a $9 million first round of financing for InXpo, the Chicago-based startup announced. Founded in 2004, InXpo creates virtual events and virtual business environments for corporate clients including AAA, Cisco, Procter & Gamble, and SAP as well as publishers such as Forbes Media, PennWell, TechTarget, and Ziff Davis. “In … Continue reading “Highland Leads $9M InXpo Deal”
Federal Judge Rules in Biogen Idec’s Favor, Sepracor Agrees to $2.8B Buyout, FDA Panel Endorses Gloucester Pharma Drug, & More Boston-Area Life Sciences News
The buyout of Sepracor was probably the biggest piece of New England life sciences news this past week, but it certainly wasn’t the only one. —Cambridge, MA-based Quanterix named David Okrongly its new CEO. Founding CEO Nicholas Naclerio will continue to server as chairman of the company, which is developing single-molecule analysis tools for diagnosing … Continue reading “Federal Judge Rules in Biogen Idec’s Favor, Sepracor Agrees to $2.8B Buyout, FDA Panel Endorses Gloucester Pharma Drug, & More Boston-Area Life Sciences News”
Calling All WordPress/PHP/Apache/Linux Gurus—Particularly the Ones With Pagers
As we’ve grown Xconomy.com over the last few years, we’ve prided ourselves on keeping our operations lean and mean, in no small part by making the most of DIY technologies and virtual working arrangements. But every once in a while—say when a bitchy little worm wiggles its way through WordPress sites across the Web—we’re reminded … Continue reading “Calling All WordPress/PHP/Apache/Linux Gurus—Particularly the Ones With Pagers”
Sepracor Snatched up for $2.6B, EMC Acquires FastScale and Kazeon, Biogen Makes Bid For Facet, & More Boston-Area Deals News
The pace of New England tech and life sciences deal making was swift over the last week and a half—and there was noticeable bump in M&A transactions. —Boston-based RockPort Capital Partners participated in a $47 million financing round for Norwegian electric vehicle maker Think. —iWalk of Cambridge, MA, picked up an undisclosed amount of new … Continue reading “Sepracor Snatched up for $2.6B, EMC Acquires FastScale and Kazeon, Biogen Makes Bid For Facet, & More Boston-Area Deals News”
$40.4M Blows In For First Wind
First Wind, the Newton, MA-based developer and operator of wind farms, nabbed $40.4 million in federal financing for a planned installation at Stetson Ridge in Maine, Mass High Tech reports. The project is one of 12 to receive a combined $500 million under the American Recovery and Reinvestment Act. Wade wrote about the challenges First … Continue reading “$40.4M Blows In For First Wind”
Pickett to Relinquish Biogen Idec Board Seat, New Financing for iWalk, Genocea Goes After Vaccine Market, & More Boston-Area Life Sciences News
New England’s life sciences startups gave us a lot to write about last week. —Luke talked with Genocea Biosciences CEO Staph Bakali about his Cambridge, MA-based startup’s strategy for developing new vaccines. The approach, based on research at Harvard Medical School, helped Genocea garner $23 million in venture capital earlier this year and has drawn … Continue reading “Pickett to Relinquish Biogen Idec Board Seat, New Financing for iWalk, Genocea Goes After Vaccine Market, & More Boston-Area Life Sciences News”
$14M for Novomer, $7.3M for Innocentive, $6M for Zendesk, & More Boston-Area Deals News
In what I think is a first for the deals roundup, it was all venture all the time for New England’s tech and life sciences companies this past week. —Greentech Media, the Cambridge, MA-based media, market research, and events company, collected $825,000 of a planned $1.25 extension of its Series B round, which previously totaled … Continue reading “$14M for Novomer, $7.3M for Innocentive, $6M for Zendesk, & More Boston-Area Deals News”